サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：糖尿病性網膜症の世界市場-2022-2029
市場調査レポート
商品コード
1166532

糖尿病性網膜症の世界市場-2022-2029

Global Diabetic Retinopathy Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
糖尿病性網膜症の世界市場-2022-2029
出版日: 2022年11月30日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場の概要

糖尿病は網膜の血管に害を及ぼし、糖尿病性網膜症（DR）と呼ばれます。この疾患には、非増殖性DRと増殖性または進行性DRの2つのタイプがあります。血糖値の変化により、目の中の光に敏感な組織が異常に増殖することで起こります。視野に黒い斑点や浮き糸が現れ、かすみ目や不規則な視界、色覚の低下、さらには視力の低下も見られます。治療法としては、ステロイドの眼内注射、レーザー手術、硝子体手術などがあります。また、フルオレセイン血管造影や光干渉断層計などの検査で診断することができます。

市場力学

糖尿病の有病率の増加、糖尿病に起因する失明の発生率の上昇、眼科手術機器や診断機器の技術的進歩により糖尿病網膜症が可能になることが、予測期間において市場を牽引する要因となっています。

糖尿病性網膜症の診断における技術的進歩は、市場成長の原動力になると予想されます。

Retina Labs社は、糖尿病性網膜症やその他の眼疾患に対する遠隔網膜スクリーニングのパイオニアです。クラウドでホストされるiVision遠隔眼科プラットフォームは、高度な眼球画像、臨床解釈および報告ツール、電子紹介を組み合わせた統合ソリューションを提供します。iVisionは、糖尿病性眼疾患のケアギャップを解消し、転帰を改善し、コストを削減することを目指す医療システム、プライマリーケアプロバイダー、医療計画向けに設計された遠隔眼科プラットフォームです。このように、上記の要因から、予測期間中に市場が牽引されることが期待されます。

糖尿病性網膜症の治療薬に伴う副作用が、市場成長の妨げになると予想されます。

ルセンティス（ラニビズマブ）」の重大な副作用には、眼球内の感染症、白内障、網膜剥離などがあり、かすみ目、光過敏、視界の曇りなどを引き起こす可能性があります。また、注射の前後に眼圧が上昇した患者さんもいます。さらに、心臓発作や脳卒中など、血栓に関連する致命的な問題が発生する場合もあります。致命的な事象は少ないもの、死因は進行した糖尿病合併症の患者さんに典型的に見られるものでした。このように、上記の要因から、予測期間中に市場が阻害されることが予想されます。

COVID-19の影響分析

COVID-19は、糖尿病性網膜症（DR）市場にマイナスの影響を与えました。国際失明防止機関（IAPB）のレポート2021によると、場所や組織の種類に関係なく、誰もが本質的に影響を受けた。少なくとも60％のDRイニシアチブは、予算が削減されるか、完全に放棄されました。DRサービスの変化は、複数の疾患を持つ高齢者患者に最も大きな影響を与えます。サービスへのアクセスの低下は、遠隔地や社会経済的地位の低さによって大きな影響を受ける。また、最も影響を受けるのは、あらゆるレベルのヘルスケア専門家です。また、道具や薬の購入に関する新たな障害、目標の変更やそれに伴う報告によってもたらされる管理負担の増加、目の健康を改善するための取り組みのための資金確保が難しくなっていることも、この市場に影響を与えています。

さらに、サービスを維持するための戦略として、遠隔眼科や患者管理システムの導入、複雑ではあるが弾力的なサービスを提供する上で重要となりうるタスク・シフティング、非対面コミュニケーション・チャネルへの依存度の向上などが一般的でした。このように、上記の要因から、市場は影響を受け、予測期間中に改善されることが期待されるようになっています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 糖尿病性網膜症診断の技術的進歩が市場成長を牽引すると予測
    • 抑制要因
      • 糖尿病性網膜症の治療薬に伴う副作用が市場成長の妨げになると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • サプライチェーン
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 適応症タイプ別

  • 非増殖糖尿病性網膜症
  • 増殖糖尿病性網膜症

第8章 治療薬タイプ別

  • 抗血管内皮細胞増殖因子（VEGF）製剤
    • ラニビズマブ（ルセンティス）
    • アフリベルセプト硝子体内注射剤（アイリーア）
    • その他
  • ステロイド眼内注射
  • レーザー手術
  • 硝子体手術
  • その他

第9章 エンドユーザー別

  • エンドユーザー
    • 病院
    • 眼科クリニック
    • 外来手術センター
    • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第12章 企業プロファイル

  • Abbott Laboratories
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Alimera Science
  • Allergan plc
  • Ampio Pharmaceuticals.
  • Bayer AG
  • Hoffmann-La Roche
  • Novartis International AG
  • Glycadia Pharmaceuticals
  • Regeneron Pharmaceuticals Inc.
  • Valeant Pharmaceutical

第13章 糖尿病性網膜症の世界市場 - DataM

目次
Product Code: DMPH29

Market Overview

Diabetes mellitus harms the retina's blood vessels, referred to as diabetic retinopathy (DR). There are two different types of this condition: non-proliferative DR and proliferative or advanced DR. It is brought on by changes in blood glucose levels, which cause the light-sensitive tissues in the eye to grow abnormally. Dark spots or floating strings can be seen in the field of vision, along with blurred or erratic vision, reduced color perception, and even loss of vision. Treatment options include intraocular steroid injection, laser surgery, and vitrectomy. It can be diagnosed using tests like fluorescein angiography and optical coherence tomography.

Market Dynamics

The increasing prevalence of diabetes, rising incidence of diabetes-related blindness, and technological advancements in ophthalmic surgical and diagnostic instruments will enable diabetic retinopathy are the factors to drive the market in the forecast period.

Technological advancement in diagnosing diabetic retinopathy is expected to drive market growth.

Retina Labs has pioneered teleretinal screening for diabetic retinopathy and other ocular disorders. The iVision teleophthalmology platform, hosted in the cloud, provides an integrated solution that combines advanced ocular imaging, clinical interpretation and reporting tools, and electronic referrals. The company's solutions enable healthcare providers to improve access to high-quality eye care while streamlining processes for managing chronic eye diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration, and retinopathy of prematurity. iVision is a teleophthalmology platform designed for health systems, primary care providers, and health plans looking to close care gaps in diabetic eye disease, improve outcomes, and lower costs. Thus, from the above factors, the market is expected to drive in the forecast period.

Side effects associated with the drugs treating diabetic retinopathy are expected to hamper the market growth.

The serious side effects of the LUCENTIS (ranibizumab) drug include infections inside the eye, cataracts, and detached retinas, which can cause blurry vision, light sensitivity, and cloudy vision. Some patients have experienced increased eye pressure before and after injection-moreover, sometimes fatal, blood clot-related problems, such as heart attacks or strokes. Although there were only a few fatal events, the causes of death were typical of patients with advanced diabetic complications. Thus, from the above factors, the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

COVID-19 impacted the diabetic retinopathy(DR) market negatively. According to the International Agency for the Prevention of Blindness (IAPB) report 2021, everybody was essentially affected, regardless of their location or type of organization. At least 60% of DR initiatives had their budgets cut or were completely abandoned. Changes in DR services have the biggest effects on elderly patients with multiple diseases. Reduced access to services is significantly impacted by remoteness and low socioeconomic status. The most impacted individuals are also all levels of healthcare professionals. The market is also affected by new obstacles related to the purchase of tools and medications, a rise in the administrative burden brought on by shifting targets and associated reporting, and growing difficulty in securing funding for initiatives to improve eye health.

Furthermore, the introduction of teleophthalmology and patient flow management were common strategies to retain services, as was task shifting, which was complex but potentially important in providing resilient services, and increased reliance on non-face-to-face communication channels. Thus, from the above factors, the market got affected and is expected to improve in the forecast period.

Segment Analysis

Laser Surgery segment is expected to hold the largest market share in diabetic retinopathy

The laser surgery segment accounted for the largest market share in 2021. Laser treatment usually works well to prevent vision loss before the retina has been severely damaged. Macular edema may benefit as well. This can reduce the swelling of the retina. Laser surgery can also helps in shrinking blood vessels and prevent them from growing again.

Moreover, severe proliferative retinopathy is treated using a more aggressive laser therapy known as scattering (pan-retinal) photocoagulation. It allows doctors to control the spread of new blood vessels across the retina's back. Therefore, there is increased demand for laser surgery for treating diabetic retinopathy. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global diabetic retinopathy market

North America region accounted for the largest market share in 2021. The increasing prevalence of diabetes, the rising geriatric population, increasing FDA approvals in the region and increasing awareness about diabetic retinopathy among people are the factors to drive the market in the forecast period. For instance, according to the IDF Diabetes Atlas 10th Edition, an estimated 51 million adults aged 20-29 were living with diabetes in the IDF NAC region in 2021, representing a regional prevalence of 14.6%. The region has the second-highest number of children and adolescents with type 1 diabetes (193,000).

Additionally, on June 29, 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. FDA has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application (sBLA) for every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR). The target action date for the FDA decision is on February 28, 2023. Thus, from the above-mentioned factors, the North America region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the diabetic retinopathy market are Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals, Bayer AG, Hoffmann-La Roche, Novartis International AG, Glycadia Pharmaceuticals, Regeneron Pharmaceuticals Inc and Valeant Pharmaceutical.

Regeneron Pharmaceuticals, Inc.:

Overview:

Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown in 1988. The company engages in the discovery, invention, development, manufacture, and commercialization of medicines. The biopharmaceutical company develops and manufactures medicines designed to treat a range of illnesses, including asthma, chronic pain, cancer, and infectious diseases. Product portfolio includes the following brands such as EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Product Portfolio:

EYLEA (AFLIBERCEPT) INJECTION: EYLEA is the only vascular endothelial growth factor (VEGF) inhibitor approved with two dosing options for diabetic retinopathy (DR). EYLEA helps in treating all stages of diabetic retinopathy (DR), thereby reducing the risk of blindness.

The global diabetic retinopathy market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement in diagnosing diabetic retinopathy is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs treating diabetic retinopathy are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Indication Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 7.1.2. Market Attractiveness Index, By Indication Type
  • 7.2. Non-Proliferative Diabetic Retinopathy*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Proliferative Diabetic Retinopathy

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Anti-Vascular Endothelial Growth Factor (VEGF)*
      • 8.2.1.1. Ranibizumab (Lucentis)*
      • 8.2.1.2. Introduction
      • 8.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 8.2.1.4. Aflibercept intravitreal (Eylea)
      • 8.2.1.5. Others
  • 8.3. Intraocular Steroid Injection
  • 8.4. Laser Surgery
  • 8.5. Vitrectomy
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. End user*
      • 9.2.1.1. Hospitals
      • 9.2.1.2. Introduction
      • 9.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 9.2.1.4. Ophthalmic Clinics
      • 9.2.1.5. Ambulatory Surgical Center
      • 9.2.1.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Alimera Science
  • 12.3. Allergan plc
  • 12.4. Ampio Pharmaceuticals.
  • 12.5. Bayer AG
  • 12.6. Hoffmann-La Roche
  • 12.7. Novartis International AG
  • 12.8. Glycadia Pharmaceuticals
  • 12.9. Regeneron Pharmaceuticals Inc.
  • 12.10. Valeant Pharmaceutical

LIST NOT EXHAUSTIVE

13. Global Diabetic Retinopathy Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us